1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hemophilia B-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Hemophilia B-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hemophilia B Report is to understand the market and pipeline status of the drugs around the Hemophilia B to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Hemophilia B. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Hemophilia B.
- A review of the marketed products under prescription for Hemophilia B, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Hemophilia B with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Hemophilia B drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Hemophilia B drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Hemophilia B drugs.
- Coverage of Hemophilia B Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Hemophilia B key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Hemophilia B.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Hemophilia B.
- API intelligence over marketed drugs forHemophilia Band gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Hemophilia B.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Hemophilia B-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Hemophilia B
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Hemophilia B
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Hemophilia B
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Hemophilia B Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Hemophilia B Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Hemophilia B Therapeutic Market, US, (Year), 2017
- Hemophilia B Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Hemophilia B Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Hemophilia B Drugs, API Manufacturers, Europe by Country, 2017
- Hemophilia B Drugs, API Manufacturers, India by State, 2017
- Hemophilia B Drugs, API Manufacturers, China by Province, 2017
- Hemophilia B Drugs, API Manufacturers by Geography 2017
- Hemophilia B Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Hemophilia B Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Hemophilia B, 2017
- Discontinued Drugs for Hemophilia B, 2017


List of Figures

- Hemophilia B Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Hemophilia B Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Hemophilia B Therapeutic Market, US, (Year), 2017
- Hemophilia B Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Hemophilia B Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Hemophilia B Drugs, API Manufacturers, Europe by Country, 2017
- Hemophilia B Drugs, API Manufacturers, India by State, 2017
- Hemophilia B Drugs, API Manufacturers, China by Province, 2017
- Hemophilia B Drugs, API Manufacturers by Geography 2017
- Hemophilia B Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Hemophilia B Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    10 pages
  • Blood Disease  

    Blood Supply  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    8 pages
  • Blood Disease  

    Cytokine  

    Cancer  

  • United States  

View report >

Related Market Segments :

Blood Disease
Cloud Computing

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.